Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SB 728 T

Drug Profile

SB 728 T

Alternative Names: CCR5-ZFN; SB 728mR T; SB-728-modified-T-cells; SB-728-T; SB-728-T-CCR5-gene-therapy; ZFP Therapeutic

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Antivirals; Cell therapies; Gene therapies; T lymphocyte cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 31 Dec 2020 Discontinued - Phase-II for HIV infections in USA, Puerto Rico (IV)
  • 12 Jun 2019 Case Western Reserve University initiates enrolment in the TRAILBLAZER phase I/II trial for HIV infections in USA (NCT03666871)
  • 04 Mar 2019 Additional efficacy and adverse events data from a phase I trial in HIV infections presented at the 26th Conference on Retroviruses and Opportunistic Infections (CROI-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top